Literature DB >> 17635891

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.

Sandeep Bansal1, Julie E Buring, Nader Rifai, Samia Mora, Frank M Sacks, Paul M Ridker.   

Abstract

CONTEXT: The association of triglycerides with incident cardiovascular disease remains controversial. Although triglyceride levels are typically obtained in the fasting state, postprandial hypertriglyceridemia may play an important role in atherosclerosis.
OBJECTIVE: To determine the association of triglyceride levels (fasting vs nonfasting) and risk of future cardiovascular events. DESIGN, SETTING, AND PARTICIPANTS: Prospective study of 26,509 initially healthy US women (20,118 fasting and 6391 nonfasting) participating in the Women's Health Study, enrolled between November 1992 and July 1995 and undergoing follow-up for a median of 11.4 years. Triglyceride levels were measured in blood samples obtained at time of enrollment. MAIN OUTCOME MEASURE: Hazard ratios for incident cardiovascular events (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death).
RESULTS: At baseline, triglyceride levels in fasting as well as nonfasting women correlated with traditional cardiac risk factors and markers of insulin resistance. During a median follow-up of 11.4 years, 1001 participants experienced an incident cardiovascular event (including 276 nonfatal myocardial infarctions, 265 ischemic strokes, 628 coronary revascularizations, and 163 cardiovascular deaths), for an overall rate of 3.46 cardiovascular events per 1000 person-years of follow-up. After adjusting for age, blood pressure, smoking, and use of hormone therapy, both fasting and nonfasting triglyceride levels predicted cardiovascular events. Among fasting participants, further adjustment for levels of total and high-density lipoprotein cholesterol and measures of insulin resistance weakened this association (fully adjusted hazard ratio [95% confidence interval] for increasing tertiles of triglyceride levels: 1 [reference], 1.21 [0.96-1.52], and 1.09 [0.85-1.41] [P = .90 for trend]). In contrast, nonfasting triglyceride levels maintained a strong independent relationship with cardiovascular events in fully adjusted models (hazard ratio [95% confidence interval] for increasing tertiles of levels: 1 [reference], 1.44 [0.90-2.29], and 1.98 [1.21-3.25] [P = .006 for trend]). In secondary analyses stratified by time since participants' last meal, triglyceride levels measured 2 to 4 hours postprandially had the strongest association with cardiovascular events (fully adjusted hazard ratio [95% confidence interval] for highest vs lowest tertiles of levels, 4.48 [1.98-10.15] [P<.001 for trend]), and this association progressively decreased with longer periods of fasting.
CONCLUSIONS: In this cohort of initially healthy women, nonfasting triglyceride levels were associated with incident cardiovascular events, independent of traditional cardiac risk factors, levels of other lipids, and markers of insulin resistance; by contrast, fasting triglyceride levels showed little independent relationship.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635891     DOI: 10.1001/jama.298.3.309

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  448 in total

1.  Macronutrient, Energy, and Bile Acid Metabolism Pathways Altered Following a Physiological Meal Challenge, Relative to Fasting, among Guatemalan Adults.

Authors:  Elaine A Yu; Tianwei Yu; Dean P Jones; Reynaldo Martorell; Manuel Ramirez-Zea; Aryeh D Stein
Journal:  J Nutr       Date:  2020-08-01       Impact factor: 4.798

2.  Higher high-density lipoprotein cholesterol in African-American women with polycystic ovary syndrome compared with Caucasian counterparts.

Authors:  Kathryn W Koval; Tracy L Setji; Eric Reyes; Ann J Brown
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

Review 3.  The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?

Authors:  Arne Astrup; Jørn Dyerberg; Peter Elwood; Kjeld Hermansen; Frank B Hu; Marianne Uhre Jakobsen; Frans J Kok; Ronald M Krauss; Jean Michel Lecerf; Philippe LeGrand; Paul Nestel; Ulf Risérus; Tom Sanders; Andrew Sinclair; Steen Stender; Tine Tholstrup; Walter C Willett
Journal:  Am J Clin Nutr       Date:  2011-01-26       Impact factor: 7.045

4.  Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.

Authors:  H Carlijne Hassing; Hans Mooij; Shuling Guo; Brett P Monia; Keyang Chen; Wim Kulik; Geesje M Dallinga-Thie; Max Nieuwdorp; Erik S G Stroes; Kevin Jon Williams
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

5.  Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011.

Authors:  K Walenta; J M Sinning; C Werner; M Böhm
Journal:  Clin Res Cardiol       Date:  2011-09-30       Impact factor: 5.460

Review 6.  [Severe hypertriglyceridemia : Diagnostics and new treatment principles].

Authors:  U Kassner; M Dippel; E Steinhagen-Thiessen
Journal:  Internist (Berl)       Date:  2017-08       Impact factor: 0.743

7.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

Authors:  Helen B Hartman; Stephen J Gardell; Chris J Petucci; Shuguang Wang; Julie A Krueger; Mark J Evans
Journal:  J Lipid Res       Date:  2009-01-27       Impact factor: 5.922

8.  Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans.

Authors:  Richard D Mattes
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-12       Impact factor: 4.052

9.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

10.  Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy.

Authors:  Erdembileg Anuurad; Asha Thomas-Geevarghese; Sridevi Devaraj; Jeanine Albu; Robert Minolfo; Wafaa M El-Sadr; Guijing Lu; Wahida Karmally; Lars Berglund
Journal:  Atherosclerosis       Date:  2007-11-09       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.